Business
ImmuCell Corporation to Present at Lytham Partners Virtual Investor Conference
On Tuesday, May 20th at 11:00 am ET PORTLAND, Maine, May 14, 2020 /PRNewswire/ -- ImmuCell Corporation (NASDAQ: ICCC) a growing animal health company that
About this update from Immucell Corporation
[{"type":"text","content":"On Tuesday, May 20th at 11:00 am ET\n\n\nPORTLAND, Maine, May 14, 2020 /PRNewswire/ -- ImmuCell Corporation (NASDAQ: ICCC) a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef calves, today announced it will participate in a virtual presentation and fireside chat at the May 2020 Lytham Partners Virtual Investor Conference on Wednesday, May 20, 2020 at 11:00am ET (8:00am PT).\nA webcast of the presentation will be posted under the investor relations section of the ImmuCell website at www.immucell.com or can be accessed at https://www.webcaster4.com/Webcast/Page/1214/34875. A replay of the presentation will be available following the event.\nManagement will also be participating in virtual one-on-one meetings on May 21, 2020. To arrange a meeting, please contact Joe Diaz of Lytham Partners at [email protected] or visit www.lythampartners.com/virtual. \nAbout ImmuCell: ImmuCell Corporation's (Nasdaq: ICCC) purpose is to create scientifically-proven and practical products that improve the health and productivity of dairy and beef calves. ImmuCell manufactures and markets First Defense®, providing Immediate Immunity™ to newborn dairy and beef calves, and is in the late stages of developing Re-Tain™, a novel treatment for subclinical mastitis without a milk discard requirement that provides an alternative to traditional antibiotics. Press releases and other information about the Company are available at: http://www.immucell.com.\nCautionary Note Regarding Forward-Looking Statements (Safe Harbor Statement): This Press Release contains \"forward-looking statements\" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to: our plans and strategies for our business; projections of future financial or operational performance; the timing and outcome of pending or anticipated applications for regulatory approvals; factors that may affect the dairy and beef industries and future demand for our products; the extent, nature and duration of the COVID-19 pandemic and its consequences, and their direct and indirect impacts on the Company's production activities, operating results and...